PE41796A1 - Compuesto activo en el receptor de serotonina 5-ht, util en el tratamiento de enfermedades del s.n.c. - Google Patents
Compuesto activo en el receptor de serotonina 5-ht, util en el tratamiento de enfermedades del s.n.c.Info
- Publication number
- PE41796A1 PE41796A1 PE1995278830A PE27883095A PE41796A1 PE 41796 A1 PE41796 A1 PE 41796A1 PE 1995278830 A PE1995278830 A PE 1995278830A PE 27883095 A PE27883095 A PE 27883095A PE 41796 A1 PE41796 A1 PE 41796A1
- Authority
- PE
- Peru
- Prior art keywords
- diseases
- treatment
- useful
- active compound
- serotonin receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Otolaryngology (AREA)
- Anesthesiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Optical Integrated Circuits (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9418326A GB9418326D0 (en) | 1994-09-12 | 1994-09-12 | Pharmaceutical compounds |
| GBGB9511166.2A GB9511166D0 (en) | 1995-06-02 | 1995-06-02 | Pharmaceutical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE41796A1 true PE41796A1 (es) | 1996-10-21 |
Family
ID=26305611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1995278830A PE41796A1 (es) | 1994-09-12 | 1995-09-12 | Compuesto activo en el receptor de serotonina 5-ht, util en el tratamiento de enfermedades del s.n.c. |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0705832B1 (OSRAM) |
| JP (1) | JPH0881464A (OSRAM) |
| KR (1) | KR960010635A (OSRAM) |
| CN (1) | CN1045602C (OSRAM) |
| AT (1) | ATE247114T1 (OSRAM) |
| AU (1) | AU698580B2 (OSRAM) |
| CA (1) | CA2157998A1 (OSRAM) |
| CZ (1) | CZ286565B6 (OSRAM) |
| DE (1) | DE69531476T2 (OSRAM) |
| ES (1) | ES2204932T3 (OSRAM) |
| FI (1) | FI954243A7 (OSRAM) |
| HU (1) | HU219491B (OSRAM) |
| IL (1) | IL115236A (OSRAM) |
| IN (1) | IN179550B (OSRAM) |
| MY (1) | MY132009A (OSRAM) |
| NO (1) | NO305174B1 (OSRAM) |
| NZ (1) | NZ272961A (OSRAM) |
| PE (1) | PE41796A1 (OSRAM) |
| PH (1) | PH31631A (OSRAM) |
| PL (1) | PL310373A1 (OSRAM) |
| RU (1) | RU2146256C1 (OSRAM) |
| TR (1) | TR199501114A2 (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2308362A (en) * | 1995-12-19 | 1997-06-25 | Lilly Industries Ltd | Pharmaceutical indole derivatives |
| EP0905136A1 (en) | 1997-09-08 | 1999-03-31 | Janssen Pharmaceutica N.V. | Tetrahydro gamma-carbolines |
| UA70334C2 (en) * | 1998-10-06 | 2004-10-15 | Janssen Pharmaceutica N V Jans | BENZOTHIENO[3,2-c]PYRIDINES AS a2 ANTAGONISTS BENZOTHIENO[3,2-c]PYRIDINES AS a2 ANTAGONISTS |
| UA74826C2 (en) * | 2000-05-17 | 2006-02-15 | Ortho Mcneil Pharm Inc | ?-carboline derivatives as phosphodiesterase inhibitors |
| AU2001278875B2 (en) * | 2000-07-06 | 2007-06-07 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Tetrahydrobenzothiazole analogues as neuroprotective agents |
| DE10040016A1 (de) * | 2000-08-16 | 2002-02-28 | Boehringer Ingelheim Pharma | Neue beta-Amyloid Inhibitoren, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| CA2417081C (en) * | 2000-09-19 | 2008-08-05 | Enzo Cereda | New n, n'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors |
| US6586435B2 (en) | 2000-09-19 | 2003-07-01 | Boehringer Ingelheim Pharma Kg | Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors |
| JP5062939B2 (ja) * | 2000-09-19 | 2012-10-31 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | セロトニン受容体及びドーパミン受容体にアフィニティーを示す新規ｎ，ｎ’−二置換ベンゾイミダゾロン誘導体 |
| US7183410B2 (en) | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
| CA2453537A1 (en) * | 2001-08-08 | 2003-02-20 | Pharmacia & Upjohn Company | Therapeutic 1h-pyrido¬4,3-b|indoles |
| UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
| RU2232578C1 (ru) * | 2003-04-10 | 2004-07-20 | Ахапкина Валентина Ивановна | Вещество, обладающее антидепрессивной активностью |
| ES2646326T3 (es) | 2005-08-03 | 2017-12-13 | Sprout Pharmaceuticals, Inc. | Uso de flibanserina en el tratamiento de la obesidad |
| WO2007048803A1 (en) | 2005-10-29 | 2007-05-03 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
| EP2037927B1 (en) | 2006-06-30 | 2010-01-27 | Boehringer Ingelheim International GmbH | Flibanserin for the treatment of urinary incontinence and related diseases |
| CL2007002214A1 (es) | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
| WO2008019996A2 (en) | 2006-08-14 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Formulations of flibanserin and method for manufacturing the same |
| JP5220746B2 (ja) | 2006-08-25 | 2013-06-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 制御放出システム及びその製造方法 |
| PE20091188A1 (es) | 2007-09-12 | 2009-08-31 | Boehringer Ingelheim Int | Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen |
| MX2011012537A (es) * | 2009-05-29 | 2011-12-14 | Sumitomo Chemical Co | Agente para el tratamiento o prevencion de enfermedades asociadas con actividad de factores neurotroficos. |
| RU2745742C1 (ru) | 2015-10-01 | 2021-03-31 | Олема Фармасьютикалз, Инк. | ТЕТРАГИДРО-1Н-ПИРИДО[3,4-b]ИНДОЛЬНЫЕ АНТИЭСТРОГЕННЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА |
| CN114302722A (zh) | 2019-07-07 | 2022-04-08 | 奥列马制药公司 | 雌激素受体拮抗剂方案 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4035369A (en) | 1975-10-08 | 1977-07-12 | Janssen Pharmaceutica N.V. | 1-Benzazolylalkyl-4-substituted-piperidines |
| IL69132A (en) * | 1982-07-14 | 1986-02-28 | Roussel Uclaf | Benzo-and naphtho-thiopyranopyrimidinones,their preparation and pharmaceutical compositions containing them |
| US4636563A (en) * | 1985-09-16 | 1987-01-13 | American Home Products Corporation | Antipsychotic γ-carbolines |
| FR2661177A1 (fr) * | 1990-04-23 | 1991-10-25 | Rhone Poulenc Sante | Derives du naphtosultame antagonistes de la serotonine, leur preparation et les medicaments les contenant. |
-
1995
- 1995-09-07 ES ES95306253T patent/ES2204932T3/es not_active Expired - Lifetime
- 1995-09-07 DE DE69531476T patent/DE69531476T2/de not_active Expired - Fee Related
- 1995-09-07 EP EP95306253A patent/EP0705832B1/en not_active Expired - Lifetime
- 1995-09-07 AT AT95306253T patent/ATE247114T1/de not_active IP Right Cessation
- 1995-09-08 PH PH51266A patent/PH31631A/en unknown
- 1995-09-08 HU HU9502631A patent/HU219491B/hu not_active IP Right Cessation
- 1995-09-08 NZ NZ272961A patent/NZ272961A/en unknown
- 1995-09-08 MY MYPI95002675A patent/MY132009A/en unknown
- 1995-09-08 CZ CZ19952322A patent/CZ286565B6/cs not_active IP Right Cessation
- 1995-09-08 AU AU30497/95A patent/AU698580B2/en not_active Ceased
- 1995-09-11 NO NO953575A patent/NO305174B1/no not_active IP Right Cessation
- 1995-09-11 JP JP7231873A patent/JPH0881464A/ja active Pending
- 1995-09-11 CA CA002157998A patent/CA2157998A1/en not_active Abandoned
- 1995-09-11 IL IL115236A patent/IL115236A/en not_active IP Right Cessation
- 1995-09-11 PL PL95310373A patent/PL310373A1/xx unknown
- 1995-09-11 RU RU95115522A patent/RU2146256C1/ru active
- 1995-09-11 CN CN95117133A patent/CN1045602C/zh not_active Expired - Fee Related
- 1995-09-11 IN IN1079CA1995 patent/IN179550B/en unknown
- 1995-09-11 KR KR1019950029475A patent/KR960010635A/ko not_active Ceased
- 1995-09-11 FI FI954243A patent/FI954243A7/fi unknown
- 1995-09-12 TR TR95/01114A patent/TR199501114A2/xx unknown
- 1995-09-12 PE PE1995278830A patent/PE41796A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PL310373A1 (en) | 1996-03-18 |
| MY132009A (en) | 2007-09-28 |
| AU698580B2 (en) | 1998-11-05 |
| AU3049795A (en) | 1996-03-28 |
| HUT72593A (en) | 1996-05-28 |
| CN1045602C (zh) | 1999-10-13 |
| FI954243A7 (fi) | 1996-03-13 |
| CZ286565B6 (cs) | 2000-05-17 |
| FI954243A0 (fi) | 1995-09-11 |
| NZ272961A (en) | 1998-02-26 |
| PH31631A (en) | 1999-01-12 |
| HU9502631D0 (en) | 1995-11-28 |
| DE69531476D1 (de) | 2003-09-18 |
| HU219491B (hu) | 2001-04-28 |
| CZ232295A3 (en) | 1996-03-13 |
| EP0705832A1 (en) | 1996-04-10 |
| IL115236A (en) | 1998-06-15 |
| EP0705832B1 (en) | 2003-08-13 |
| NO953575D0 (no) | 1995-09-11 |
| CA2157998A1 (en) | 1996-03-13 |
| KR960010635A (ko) | 1996-04-20 |
| NO953575L (no) | 1996-03-13 |
| IN179550B (OSRAM) | 1997-10-18 |
| CN1129219A (zh) | 1996-08-21 |
| JPH0881464A (ja) | 1996-03-26 |
| NO305174B1 (no) | 1999-04-12 |
| ES2204932T3 (es) | 2004-05-01 |
| ATE247114T1 (de) | 2003-08-15 |
| DE69531476T2 (de) | 2004-06-09 |
| TR199501114A2 (tr) | 1996-10-21 |
| RU2146256C1 (ru) | 2000-03-10 |
| IL115236A0 (en) | 1995-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE41796A1 (es) | Compuesto activo en el receptor de serotonina 5-ht, util en el tratamiento de enfermedades del s.n.c. | |
| PE20030039A1 (es) | Derivados de indol con afinidad por el receptor 5-ht6 | |
| ATE177099T1 (de) | Diazabicyclische neurokinin antagonisten | |
| UY24016A1 (es) | Derivados triciclicos del pirazol | |
| PE20030471A1 (es) | Compuesto de imidazopiridin como moduladores del receptor 5-ht4 | |
| NZ511394A (en) | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | |
| ATE116317T1 (de) | Chinuclidinderivate. | |
| DE69504300D1 (de) | Gem-bissubstituierte azazyclische tachykinin-antagonisten | |
| ATE216996T1 (de) | Kondensierte trizyklische, stickstoffenthaltende verbindungen als substanz p rezeptor antagonisten | |
| ATE509929T1 (de) | Substituierte tricyclische gamma-carbolineals serotonin-rezeptor-agonisten und antagonisten | |
| PE34297A1 (es) | Ligandos especificos del neuropeptido y1 | |
| PE20010544A1 (es) | Derivados de mutilina utiles como agentes antibacterianos | |
| PE20040687A1 (es) | Quinolinas sustituidas como antagonistas del receptor ccr5 | |
| ATE427936T1 (de) | Substituierte piperidin-verbindungen als modulatoren der chemokine receptor aktivitat | |
| AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
| ATE404538T1 (de) | Tetrahydropyranylcyclopentyltetrahydroisochino- linmodulatoren der chemokinrezeptoraktivität | |
| PE20071245A1 (es) | COMPUESTOS INDOL SULFONAMIDA COMO MODULADORES DEL RECEPTOR DE PROGESTERONA SELECTIVOS (SPRMs) | |
| DE69331988D1 (de) | Indol derivate als 5-ht1 agoniste | |
| PE20020063A1 (es) | Bis-arilsulfonas como ligandos del receptor de 5-ht | |
| PE20020194A1 (es) | 2,3,7,8,9,10,11,12-OCTAHIDROAZEPINO[4,5-b]PIRANO[3,2-e)INDOLES SUSTITUIDOS | |
| PE20040763A1 (es) | Derivados de aminoalcoxiindoles como ligandos de los receptores 5-ht6 | |
| PE35796A1 (es) | Derivado de bencimidazol | |
| PE25998A1 (es) | DERIVADOS DE OCTAHIDRO-PIRROLO(1,2-a)-PIRAZINA 2,7-SUSTITUIDOS | |
| ATE341538T1 (de) | Benzimidazolonderivate mit affinität zu serotonin-und dopaminrezeptoren | |
| DE69727305D1 (de) | Verwendung neurogen-entzuendungshemmender verbindungen und zusammensetzungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |